Consolidated Statements of Operations (USD $)	12 Months Ended		67 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Consolidated Statements of Operations [Abstract]
Grant awards		$ 3,110	$ 585,589
Operating expenses:
Research and development	2,737,688	902,938	6,095,170
Clinical and regulatory	1,397,157	253,189	1,825,000
General and administrative	2,429,796	1,189,660	4,725,322
Total operating expenses	6,564,641	2,345,787	12,645,492
Loss from operations	(6,564,641)	(2,342,677)	(12,059,903)
Interest income	10,068	2	10,755
Other income (expense)	23,828	(7,257)	15,045
Interest expense	(79,119)	(101,086)	(298,580)
Total non-operating expenses	(45,223)	(108,341)	(272,780)
Loss from continuing operations	(6,609,864)	(2,451,018)	(12,332,683)
Loss from discontinued operations		(20,129)	(288,724)
Net Loss	(6,609,864)	(2,471,147)	(12,621,407)
Net loss - non-controlling interest	(198,516)	(50,947)	(274,777)
Beneficial conversion charge	(2,300,000)		(2,300,000)
Preferred stock dividend	(361,668)		(361,668)
Net loss attributable to common stockholders	$ (9,073,016)	$ (2,420,200)	$ (15,008,298)
Net loss per share attributable to common stockholders-basic and diluted	$ (2.42)	$ (1.32)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	3,747,357	1,831,769